Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

KRAS mutations predict response to EGFR inhibitors.

Raponi M, Winkler H, Dracopoli NC.

Curr Opin Pharmacol. 2008 Aug;8(4):413-8. doi: 10.1016/j.coph.2008.06.006. Epub 2008 Jul 19. Review.

PMID:
18619559
2.

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II.

Clin Cancer Res. 2007 May 15;13(10):2890-6.

3.

KRAS mutational testing in the selection of patients for EGFR-targeted therapies.

Garcia J, Riely GJ, Nafa K, Ladanyi M.

Semin Diagn Pathol. 2008 Nov;25(4):288-94. Review.

PMID:
19013894
4.

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.

Sánchez-Muñoz A, Gallego E, de Luque V, Pérez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E.

BMC Cancer. 2010 Apr 13;10:136. doi: 10.1186/1471-2407-10-136.

5.

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.

Chang DZ, Kumar V, Ma Y, Li K, Kopetz S.

J Hematol Oncol. 2009 Apr 22;2:18. doi: 10.1186/1756-8722-2-18. Review.

6.

EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.

Wang Z, Wu YL, Zhang GC, Zhou Q, Xu CR, Guo AL.

Onkologie. 2008 Apr;31(4):174-8. doi: 10.1159/000116736. Epub 2008 Mar 20.

PMID:
18418018
7.

[Biomarkers in solid tumors].

Nagy Z.

Magy Onkol. 2013 Mar;57(1):56-62. doi: MagyOnkol.2013.57.1.56. Epub 2013 Feb 10. Hungarian.

8.

The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer.

Lopez-Chavez A, Carter CA, Giaccone G.

Curr Opin Investig Drugs. 2009 Dec;10(12):1305-14. Review.

PMID:
19943202
9.

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS; National Cancer Institute of Canada Clinical Trials Group Study BR.21.

J Clin Oncol. 2008 Sep 10;26(26):4268-75. doi: 10.1200/JCO.2007.14.8924. Epub 2008 Jul 14.

PMID:
18626007
10.

Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.

Shibata T, Hanada S, Kokubu A, Matsuno Y, Asamura H, Ohta T, Sakamoto M, Hirohashi S.

Cancer Sci. 2007 Jul;98(7):985-91. Epub 2007 Apr 23.

11.

Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.

Jiang Y, Mackley H, Cheng H, Ajani JA.

Biomark Med. 2010 Aug;4(4):535-41. doi: 10.2217/bmm.10.74. Review.

PMID:
20701442
12.

PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.

Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T.

J Thorac Oncol. 2006 Sep;1(7):629-34.

13.

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.

Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA.

Br J Cancer. 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24.

14.

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.

de Reyniès A, Boige V, Milano G, Faivre J, Laurent-Puig P.

J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186. No abstract available.

PMID:
18445856
15.

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition.

Rouleau E, Spyratos F, Dieumegard B, Guinebretière JM, Lidereau R, Bièche I.

Br J Cancer. 2008 Dec 16;99(12):2100. doi: 10.1038/sj.bjc.6604815. No abstract available.

16.

Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.

Wen YS, Cai L, Zhang XW, Zhu JF, Zhang ZC, Shao JY, Zhang LJ.

Medicine (Baltimore). 2014 Dec;93(29):e296. doi: 10.1097/MD.0000000000000296.

17.

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH.

J Clin Oncol. 2008 Mar 20;26(9):1472-8. doi: 10.1200/JCO.2007.13.0062.

PMID:
18349398
18.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

19.

[Biological criteria of eligibility for a treatment against EGFR].

Laurent-Puig P.

Med Sci (Paris). 2009 Mar;25 Spec No 1:21-4. doi: 10.1051/medsci/2009251s21. French.

20.

Therapeutic modulation of k-ras signaling in colorectal cancer.

Krens LL, Baas JM, Gelderblom H, Guchelaar HJ.

Drug Discov Today. 2010 Jul;15(13-14):502-16. doi: 10.1016/j.drudis.2010.05.012. Epub 2010 Jun 2. Review.

PMID:
20594936

Supplemental Content

Support Center